Stock fact sheet · data as of
Grifols, S.A. (GRFS): fair value, margin of safety and Wheel Score
Healthcare · Drug Manufacturers - General · Spain · ADR · Value
Is GRFS undervalued?
At 7.54 (close of 16 Oct 2026), GRFS trades 61% below the GLS average fair value of 19.23. That average comes from 9 models run on the latest filings, and 7 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns Grifols, S.A. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
The 9 models disagree widely: DDM gives 1.21 while Payback Time gives 44.61. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files GRFS under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for GRFS
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 18.66 | +147% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 11.04 | +46% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 23.85 | +216% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 10.09 | +34% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 30.39 | +303% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 27.75 | +268% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 44.61 | +492% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | 1.21 | -84% | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend |
| EPV | 5.52 | -27% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -8.35 | -211% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
On financial health GRFS scores 7/9 (Piotroski): most of the nine tests - positive earnings and cash flow, falling debt, rising margins and turnover - are passed, which is the kind of balance sheet a wheel trader is happy to be assigned. The GLS Moat score is low at 4.5 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC 2.8%, ROE 7.3%, ROA 2.0% - with debt at 1.66 times equity and a free-cash-flow yield of 11.2%.
The dividend yield is 0.82% with a payout ratio of 28% - a small yield that leaves most of the earnings in the business. Revenue comes mainly from Haemoderivatives 86%, Transfusional medicine 8%, Other Product 3% (fiscal year FY2025).
Institutional ownership scores 3/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 7 / 9 | ROIC | 2.8% |
|---|---|---|---|
| GLS Moat | 4.5 / 10 | ROE | 7.3% |
| Debt / equity | 1.66 | ROA | 2.0% |
| Free-cash-flow yield | 11.2% | Payout ratio | 28% |
| Institutions | 3 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 83: Prime
GRFS scores 83 out of 100 on the Wheel Score, in the Prime band (80 and above), which fewer than one stock in twenty reaches on any night. The score blends five things a wheel trader checks before selling a cash-secured put: the margin of safety (Value, 25/25), Piotroski health (16/20), the GLS moat (7/15), the option premium on offer (18/20) and how easily the stock trades (17/20).
Implied volatility is 66% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (18 of 20) because volatility this high usually comes with a reason. Chain open interest is 6,215 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 907k shares a day on a market cap of $6.4B, with a beta of 1.19; the Stability part of the Wheel Score gives that 17 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 61% margin of safety | |
| Health | 16 / 20 | Piotroski 7/9 | |
| Moat | 7 / 15 | moat 4.5/10 | |
| Premium | 18 / 20 | implied volatility 66% | |
| Stability | 17 / 20 | 907k shares/day, $6.4B cap, beta 1.19 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 10 Nov 2026, 25 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - General
The 12 companies below are the closest to Grifols, S.A. by market cap within the Drug Manufacturers - General industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| OGN Organon & Co. | 13.76 | 18.60 | +26% | 66Good | $3.6B |
| BIIB Biogen Inc. | 235.35 | 197.03 | -19% | 58Fair | $34.8B |
| SNY Sanofi | 39.77 | 63.49 | +37% | 86Prime | $97.4B |
| GSK GSK plc | 49.02 | 43.72 | -12% | 70Good | $98.2B |
| BMY Bristol-Myers Squibb Company | 60.57 | 76.74 | +21% | 86Prime | $123.7B |
| PFE Pfizer Inc. | 29.21 | 19.78 | -48% | 58Fair | $166.5B |
| AMRN Amarin Corporation plc | 11.57 | 49.88 | +77% | 45Weak | $239M |
| NVO Novo Nordisk A/S | 39.22 | 173.67 | +77% | 91Prime | $174.9B |
| GILD Gilead Sciences, Inc. | 157.37 | 138.25 | -14% | 45Weak | $195.1B |
| AMGN Amgen Inc. | 434.03 | 330.55 | -31% | 65Good | $234.7B |
| AZN AstraZeneca PLC | 166.68 | 184.44 | +10% | 85Prime | $258.5B |
| NVS Novartis AG | 150.38 | 144.89 | -4% | 68Good | $285.8B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about GRFS
Is GRFS undervalued right now?
By the GLS models, yes: at 7.54 the stock is 61% below the average fair value of 19.23 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of GRFS and what does it mean?
GRFS scores 83 out of 100 (Prime). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for GRFS?
19.23 per share as of 16 Oct 2026 - the simple average of the 9 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Grifols, S.A. report earnings next?
The next earnings report is due on 10 Nov 2026, 25 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does GRFS have listed options, and how liquid are they?
Yes. The nightly snapshot found 152 listed contracts with 6,215 open interest across all expiries and implied volatility of 66% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.